Thrombolysis in Factor Xa-inhibitors Trial (SIFT)
The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)
Sponsor: Clinical Trial Unit (CTU), Oslo University Hospital
Listed as NCT06878066, this PHASE3 trial focuses on Acute Ischemic Stroke and Anticoagulant Therapy and remains actively recruiting participants. Sponsored by Clinical Trial Unit (CTU), Oslo University Hospital, it has been updated 6 times since 2025, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Trial Unit (CTU), Oslo University Hospital
- Guri Hagberg
- Klinbeforsk
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bergen, Norway , Bærum, Norway , Drammen, Norway , Grålum, Norway , Kristiansand, Norway , Lillehammer, Norway , Oslo, Norway , Stavanger, Norway , Tromsø, Norway , Trondheim, Norway and 2 more locations